INDIANAPOLIS, United States, June 9, 2026
Eli Lilly and Company has secured U.S. Food and Drug Administration (FDA) approval for an expanded maintenance dosing regimen of EBGLYSS® (lebrikizumab-lbkz), allowing eligible patients with moderate-to-severe atopic dermatitis to receive a single maintenance injection every eight weeks. The approval marks a significant advancement in the treatment landscape for chronic inflammatory skin diseases, making EBGLYSS the only approved therapy offering as few as six maintenance injections per year without requiring prescription topical therapies from the start. The decision is expected to provide greater convenience for patients while maintaining long-term disease control, addressing one of the key challenges associated with chronic eczema management. The FDA approval was supported by long-term clinical evidence demonstrating durable efficacy and safety, reinforcing Lilly’s growing leadership position in immunology and dermatology innovation.
Clinical Data Supports Long-Term Disease Control
The newly approved regimen is based on longitudinal exposure-response modeling and findings from the Phase 3 ADjoin extension study, which evaluated EBGLYSS maintenance dosing every four weeks and every eight weeks over a 32-week period in patients with moderate-to-severe atopic dermatitis. Results demonstrated that patients could maintain disease control while benefiting from a reduced treatment burden. Importantly, the study reported no new safety signals, and no participants discontinued treatment due to adverse events during the extension period.
The most commonly reported adverse reactions included conjunctivitis, injection-site reactions, and herpes zoster. Researchers noted that extending maintenance dosing intervals provides patients and healthcare providers with increased flexibility while preserving the therapeutic benefits observed in earlier clinical studies. Experts involved in the study emphasized that treatment personalization is becoming increasingly important in dermatology, particularly for patients managing chronic and relapsing inflammatory diseases that can significantly impact quality of life.
IL-13 Targeting Therapy Expands Treatment Options
Advertisement
EBGLYSS is a monoclonal antibody that selectively targets interleukin-13 (IL-13), a key driver of type 2 inflammation associated with atopic dermatitis. By inhibiting IL-13 signaling, the therapy helps reduce inflammation and improve disease symptoms in patients whose condition is inadequately controlled with topical prescription treatments. The biologic has been evaluated across an extensive global Phase 3 clinical development program involving more than 1,600 patients, including adults, adolescents, patients with skin of color, and individuals previously treated with other biologic therapies.
Since its initial approvals in the United States, Canada, Japan, and Europe, EBGLYSS has emerged as a significant option for patients requiring advanced systemic treatment. The new every-eight-week maintenance schedule further differentiates the therapy within the competitive biologics market by reducing injection frequency while maintaining efficacy. Healthcare professionals view this advancement as an important step toward improving treatment adherence and reducing the long-term burden associated with chronic eczema management.
FDA Decision Strengthens Lilly’s Immunology Portfolio
The latest FDA approval strengthens Lilly’s expanding immunology franchise and highlights the company’s commitment to developing innovative therapies for immune-mediated diseases. Atopic dermatitis affects millions of individuals worldwide and can lead to persistent itching, skin inflammation, sleep disruption, and diminished quality of life. By offering a biologic treatment with a reduced maintenance dosing schedule, Lilly aims to improve patient convenience while supporting long-term clinical outcomes. The approval also reflects continued momentum in the biologics sector, where targeted therapies are increasingly transforming the standard of care for chronic inflammatory conditions.
As healthcare systems focus on improving patient adherence and treatment effectiveness, therapies that combine strong efficacy with simplified administration schedules are expected to play a growing role in clinical practice. With this regulatory milestone, EBGLYSS further strengthens its position as a leading biologic treatment option for moderate-to-severe atopic dermatitis and underscores the ongoing evolution of precision immunology therapies.
Source: Eli Lilly press release
